Major Players - Generic Drugs Industry

Jul, 2023 - by CMI

Major Players - Generic Drugs Industry

Medication classified as a generic has the same active component as a branded drug. The therapeutic effects of these medications are same, and they are prescribed with the same dosage, quality, and usage patterns. However, compared to their branded counterparts, generic medications' inactive components can vary. These medications are primarily marketed after a branded drug's patent expires and are much less expensive than the patented branded drugs. Generic drugs are manufactured using the same safety and manufacturing practices as branded pharmaceuticals and are of comparable quality. Following the expiration of patent exclusivity, some manufacturers submit an abbreviated new drug application (ANDA) to the FDA.

Generic drug makers are focused on the development and introduction of innovative medications and formulations, such as biosimilars. When a drug's patent expires, many market players should be able to develop the generic counterpart. Furthermore, the FDA's attempt to aid in the development of biosimilars is encouraging companies to give it their full attention. Other reasons driving the growth of the generic pharmaceuticals market include an increase in the prevalence of chronic diseases. However, a lack of active pharmaceutical components is causing generics to be unavailable in the market, and increased FDA pressure on manufacturers to improve the manufacturing quality of these pharmaceuticals is impeding market growth.

Top Companies in the Generic Drugs Industry:

1. Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is an Israeli multinational pharmaceutical company. It was founded in 1901 and headquartered in Tel Aviv, Israel.. It operates in more than 60 countries. In order to position the business for a new era of growth, Teva Pharmaceutical Industries Ltd. adopted a new strategy framework with four main pillars in May 2023. With AUSTEDO®, AJOVY®, UZEDYTM, and biosimilars, this approach aims to bolster the company's robust commercial portfolio, increase its innovative pipeline, keep the company's generics powerhouse, and focus the business. These four pillars are seen to be more beneficial and to have a bigger impact on patients.

2. Mylan N.V.

Mylan N.V.  was a global generic and specialty pharmaceuticals company.  It was founded in 1961 and headquartered in PennsylvaniaUnited States. It operates in more than 165 countries and territories. In November 16, 2020 ,Mylan gives way to Viatris after nearly 60 years. With its merger with the Upjohn division of Pfizer Inc., the Canonsburg-based company has relaunched. In July 2019, combining Mylan with Upjohn, two Pfizer divisions, created a new champion for global health that is specially positioned to meet the demand for medicine around the world.

3. Novartis International AG

Novartis International AG was founded in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis had its headquarters at Basel, Switzerland. It improves and prolongs lives. It solves society's toughest healthcare problems by using modern research and technology and making new innovations. Novartis AG has partners in about 140 countries. Novartis declares its intention to completely spin off the Sandoz business in August 2022 to form a standalone company.

4. Pfizer, Inc.

Pfizer, Inc. is an American multinational pharmaceutical and biotechnology corporation, founded in 1849 and is headquartered in Williamsburgh, New York. It operates to over 181 countries. In July 2019, combining Mylan with Upjohn, two Pfizer divisions, created a new champion for global health that is specially positioned to meet the demand for medicine around the world.

5. Allergan Plc

Allergan Plc  In March 2015, the Irish company Actavis plc   bought the American company Allergan, Inc., and changed its name to Allergan. It is headquartered in Dublin, Ireland. Allergan PLC operated in approximately 100 countries.

6. Sun Pharmaceuticals

Sun Pharmaceuticals is an Indian multinational pharmaceutical company, was founded in 1983 and headquartered in Mumbai, India. It operates in more than 100 countries across the globe. Sun Pharma plans to boost R&D spending in speciality and generics industries by June 2023.

7. Sanofi

Sanofi is a French multinational pharmaceutical and healthcare company. It was founded in 1973 and headquartered in Paris, France. It operates in approximately 40 low and lower-middle income countries.

8. Abbott Healthcare

Abbott Healthcare was founded in 1997b and headquartered in Illinois,United States (USA). It operates in over 150 countries.

9. AstraZeneca Plc

AstraZeneca Plc is a British-Swedish multinational pharmaceutical and biotechnology company, was founded in 1999 and headquartered in England, UK. It operates in 100 countries.

10. Novo Nordisk

Novo Nordisk was founded in 1923 and headquartered in Copenhagen, Denmark. It operates in 80 countries and territories. As part of a deal with Teva Pharmaceuticals (Teva), Novo Nordisk said in February 2019 that it will have at least four years before having to compete with biosimilar versions of its diabetes injectable Victoza (liraglutide).Victoza is an injectable medication created by the Danish pharmaceutical company Novo Nordisk that is used to treat type 2 diabetes and obesity.

Definition: A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire

© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.